{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:03:36Z","timestamp":1784937816241,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Primary sclerosing cholangitis (PSC) represents a cholestatic disease hallmarked by persistent and progressive inflammation of the bile ducts. Despite its low incidence and unfavorable prognosis, there is no pharmacological therapy capable of altering the course of PSC, and liver transplantation is the only effective treatment. In the face of the landscape of PSC, pharmaceutical therapy encounters great challenges that demand expeditious resolution. However, at present, many drugs have been carried out to phase III clinical trials and are expected to be applied to the clinical treatment of PSC patients in the future. This review integrates relevant research findings from PubMed and Web of Science databases up to October 2024 over the past decade, excluding other liver diseases, such as fatty liver disease, viral hepatitis, and alcoholic liver disease. It covers the vast majority of drugs currently in clinical trials, and focus on the summary of hot research drugs, and summarizes the latest drug-based therapeutic for PSC. This review not only provides certain information for clinical research and treatment of PSC, but it is also the first time that stem cell therapy has been linked to PSC, which is expected to improve cholestasis and liver inflammation in patients with PSC. The article provides explanations and comparisons of different drugs, offering a basis for future researchers to choose medications.<\/jats:p>","DOI":"10.3389\/fmed.2025.1544601","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:31:55Z","timestamp":1751002315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Current status of pharmacotherapy for primary sclerosing cholangitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Hang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on sclerosing cholangitis.","volume":"77","year":"2022","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/s0039-6109(16)45290-4","article-title":"Primary sclerosing cholangitis.","volume":"70","author":"Lillemoe","year":"1990","journal-title":"Surg Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.cgh.2023.04.004","article-title":"Recent advances in the management of primary sclerosing cholangitis.","volume":"21","author":"Assis","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?","volume":"80","author":"van Munster","year":"2024","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/j.gastro.2024.01.049","article-title":"Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: Themes and concepts.","volume":"166","author":"Trivedi","year":"2024","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond.","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group.","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study.","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: Ursodeoxycholic acid for primary sclerosing cholangitis.","volume":"34","author":"Triantos","year":"2011","journal-title":"Aliment. Pharmacol. Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis.","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fmed.2020.00117","article-title":"New therapeutic targets in autoimmune cholangiopathies.","volume":"7","author":"Gerussi","year":"2020","journal-title":"Front Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis.","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.jhepr.2021.100255","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/MCG.0000000000000591","article-title":"Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: A human pilot study.","volume":"51","author":"Assis","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s00535-010-0204-x","article-title":"Bezafibrate for the treatment of primary sclerosing cholangitis.","volume":"45","author":"Mizuno","year":"2010","journal-title":"J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-spanish experience.","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/cpt.1930","article-title":"Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol.","volume":"108","author":"Ghonem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e00984","DOI":"10.1002\/prp2.984","article-title":"Fenofibrate in primary sclerosing cholangitis; A randomized, double-blind, placebo-controlled trial.","volume":"10","author":"Hatami","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1038\/s41598-021-83974-8","article-title":"Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.","volume":"11","author":"van den Hoek","year":"2021","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000450988","article-title":"Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis.","volume":"35","author":"Hegade","year":"2017","journal-title":"Dig Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0153","DOI":"10.1097\/HC9.0000000000000153","article-title":"Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.","volume":"7","author":"Bowlus","year":"2023","journal-title":"Hepatol Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/HEP.0000000000000376","article-title":"A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans.","volume":"78","author":"Caballero-Camino","year":"2023","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial.","volume":"40","author":"F\u00e4rkkil\u00e4","year":"2004","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: A pilot study.","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","article-title":"Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: An immunomodulating antibiotic.","volume":"47","author":"Davies","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jhin.2018.06.024","article-title":"Point-prevalence survey of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci in adult inpatients in a university teaching hospital in the UK.","volume":"100","author":"Wilson","year":"2018","journal-title":"J Hosp Infect"},{"key":"B36","doi-asserted-by":"publisher","first-page":"646-59; quiz 660","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: Primary sclerosing cholangitis.","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/hep4.1926","article-title":"A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis.","volume":"6","author":"Carey","year":"2022","journal-title":"Hepatol Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"108163","DOI":"10.1016\/j.pharmthera.2022.108163","article-title":"Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis.","volume":"237","author":"Liu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1111\/j.1572-0241.2000.02323.x","article-title":"Oral budesonide in the treatment of primary sclerosing cholangitis.","volume":"95","author":"Angulo","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"B40","first-page":"57","article-title":"The combination of prednisone and colchicine in patients with primary sclerosing cholangitis.","volume":"86","author":"Lindor","year":"1991","journal-title":"Am J Gastroenterol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e36126","DOI":"10.7759\/cureus.36126","article-title":"Primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: Significant barriers in liver disease diagnosis and treatment experienced by the latino community.","volume":"15","author":"Guifarro","year":"2023","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: Perseus study.","volume":"5","author":"Eksteen","year":"2020","journal-title":"Hepatol Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.jhepr.2019.100064","article-title":"A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.","volume":"2","author":"Segal-Salto","year":"2020","journal-title":"JHEP Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/S0168-8278(20)31452-5","article-title":"CCL24 modulates fibrosis development in primary sclerosing cholangitis: Correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2\u2013\/\u2013 mouse model.","volume":"73","author":"Barashi","year":"2020","journal-title":"J Hepatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e162270","DOI":"10.1172\/jci.insight.162270","article-title":"CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis.","volume":"8","author":"Greenman","year":"2023","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases.","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MPG.0000000000002855","article-title":"Vedolizumab therapy in children with primary sclerosing cholangitis: Data from the pediatric primary sclerosing cholangitis consortium.","volume":"71","author":"Laborda","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.14309\/ajg.0000000000001956","article-title":"A randomized, dose-finding, proof-of-concept study of berberine ursodeoxycholate in patients with primary sclerosing cholangitis.","volume":"117","author":"Kowdley","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes.","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12931-021-01863-0","article-title":"Dual inhibition of \u03b1v\u03b26 and \u03b1v\u03b21 reduces fibrogenesis in lung tissue explants from patients with IPF.","volume":"22","author":"Decaris","year":"2021","journal-title":"Respir Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"0207","DOI":"10.34133\/research.0207","article-title":"Human placental mesenchymal stem cells relieve primary sclerosing cholangitis via upregulation of TGR5 in Mdr2-\/- mice and human intrahepatic cholangiocyte organoid models.","volume":"6","author":"Yao","year":"2023","journal-title":"Research"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1544601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T05:31:56Z","timestamp":1751002316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1544601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":51,"alternative-id":["10.3389\/fmed.2025.1544601"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1544601","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"1544601"}}